Value of miR-31 and miR-150-3p as diagnostic and prognostic biomarkers for breast cancer
- 1 October 2024
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-9
Abstract
Background The most prevalent malignancy among women is breast cancer (BC). MicroRNAs (miRNAs) play a role in the initiation and progression of BC by influencing breast cancer stem cells (BCSCs) but the diagnostic and prognostic roles of those miRNAs on BC patients are still unknown. It was aimed to investigate expression profiles, diagnostic and prognostic potentials of BCSC-related miRNAs in different subtypes (Luminal A and B, HER2 + and TNBC) of BC patients. Methods and Results Expression analysis of 15 BCSC-related miRNAs was performed in 50 breast tumor tissues and 20 adjacent non-tumor tissues obtained from BC patients using the qRT-PCR method. The expression levels of miR-31 and miR-150-3p were significantly upregulated in the tumor tissues compared to the adjacent non-tumor tissues (p < 0.05). miR-31 expression upregulated in the Luminal A and Luminal B group compared to non-tumor tissue (p < 0.05). miR-31 expression was determined to be significantly higher in the Luminal group (Luminal A and B) compared to the aggressive group (HER2 + and TNBC) (p < 0.05). According to the ROC analysis, the area under the curve (AUC) of miR-31 and miR-150-3p were 0.66 with a sensitivity of 68% and a specificity of 70%. A significant inverse correlation was observed between miR-31 expression with metastatic carcinoma status, in situ component, and Ki67 value in tumors, and high miR-150-3p expression was correlated with p63 expression (p < 0.05). Conclusion miR-31 and miR-150-3p have the potential to serve as biomarkers for guiding diagnosis, evaluating prognosis, and metastatic process in patients with BC.Keywords
Funding Information
- Bursa Uludağ Üniversitesi (DDP(F)-2020/5.)
This publication has 27 references indexed in Scilit:
- Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) TreatmentPLOS ONE, 2016
- Breast cancer intrinsic subtype classification, clinical use and future trends.2015
- The diverse role of miR‐31 in regulating cancer associated phenotypesGenes, Chromosomes and Cancer, 2013
- Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancerOncogene, 2013
- Cancer stem cellsThe International Journal of Biochemistry & Cell Biology, 2012
- miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor statusOncology Letters, 2012
- miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancerMolecular Cancer, 2012
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 StudiesPLOS Medicine, 2010
- miR-31: A Master Regulator of Metastasis?Future Oncology, 2009
- p63 Expression in Breast CancerAmerican Journal of Surgical Pathology, 2004